An observational study in Obstructive Sleep Apnea (OSA), sponsored by Wissenschaftliches Institut Bethanien e.V. Recruiting at 18 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Sleep Apnea, Obstructive with a site in Greece — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea, Obstructive · Greece.
Among the 17 studies in Sleep Apnea, Obstructive with a site in Greece, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 16th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →3 of the 17 studies in Sleep Apnea, Obstructive with a site in Greece are open now. Recruiting first, the newest first:
Aristides Plaitis · Sites in Greece
Ages 18+
Democritus University of Thrace · Sites in Greece
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 74 across the 9 interventional studies, 117 across the 8 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 9 most frequent:
Wissenschaftliches Institut Bethanien e.V is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Wissenschaftliches Institut Bethanien e.V has 5 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Sleep Apnea, Obstructive with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate a new classification system for obstructive sleep apnoea in patients with newly diagnosed obstructive sleep apnoea and monitor for long-term objective and subjective improvement.
Patients with suspected obstructive sleep apnoea presenting for sleep medical evaluation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment is generally not recommended according to the Baveno classification
Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment should be considered based on individual assessment according to the Baveno classification
Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment is generally recommended according to the Baveno classification
Change in daytime sleepiness as measured by the Epworth Sleepiness Scale
The Epworth Sleepiness Scale total score ranges from 0-24. Higher values represent a larger extent of daytime sleepiness
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in office systolic blood pressure
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in office diastolic blood pressure
Time frame: From enrollment to the end of the individual observation period at 36 months
Cardiovascular events (MACE) occurring after study inclusion, including but not limited to myocardial infarction, stroke, hospitalisation for cardiovascular-related treatment (e.g. heart failure, arrhythmia)
Time frame: From enrollment to the end of the individual observation period at 36 months
Average OSA treatment usage
Average usage of the prescribed treatment for obstructive sleep apnea, measured as hours per day, derived from therapy device data
Time frame: From enrollment to the end of the individual observation period at 36 months
Number of patients who discontinue OSA treatment
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in Insomnia Severity Index total score
The Insomnia Severity Index (ISI) total score ranges from 0-28. Higher scores represent a larger extent of insomnia-related symptoms. Scores of 15 and above are indicative of clinical insomnia.
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in subjective sleep length
Subjective sleep length as assessed via personal interview, measured in hours per night
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in Fatigue Severity Scale mean score
The Fatigue Severity Scale (FSS) mean score ranges from 0-7, with higher values indicating a larger extent of fatigue.
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in cognitive performance as assessed by the Montreal Cognitive Assessment (MoCA) total score
The Montreal Cognitive Assessment (MoCA) total score ranges from 0-30. A higher score represents a better cognitive performance. A result of 26 or higher is considered normal.
Time frame: From enrollment to the end of the individual observation period at 36 months
Change in average oxygen desaturation area as measured by overnight oximetry
The average oxygen desaturation area (unit: s\*%) is automatically calculated from the oximetry signal of a single night poly(somno)graphy. Higher values indicate a larger extent of hypoxic burden.
Time frame: From enrollment to the end of the individual observation period at 36 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 60 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 60 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wissenschaftliches Institut Bethanien e.V